total 8 times.

2 trials

Sponsors

Keio university school of medicine

Conditions

Neurofibromatosis type 2 with progressive schwannomaRecurrent, Progressive and Refractory Brain Tumors(hemangiopericytoma, hemangioblastoma, WHO grade II or III meningioma, chordoma, ependymoma)

Phase 1

A phase I/II study for peptide vaccine of vascular endothelial growth factor receptor-1/2 in patients with progressive schwannoma from Neurofibromatosis type 2

Active, not recruitingJPRN-UMIN000023565

Keio university school of medicineNeurofibromatosis type 2 with progressive schwannoma

Start: 2016-08-09Target: 10Updated: 2026-06-29

VEGFR1/2 Peptide Vaccine in Patients with Recurrent, Progressive and Refractory Brain Tumors

RecruitingJPRN-UMIN000029005

Keio university school of medicineRecurrent, Progressive and Refractory Brain Tumors(hemangiopericytoma, hemangioblastoma, WHO grade II or III meningioma, chordoma, ependymoma)

Start: 2017-10-01Target: 20Updated: 2026-06-29

Related Papers

Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series

BMC Cancer2020-03-1226 citations